IMRN Immuron Limited

5.04
-0.08  -2%
Previous Close 5.12
Open 5.35
Price To Book 3.27
Market Cap 16199200
Shares 3,214,127
Volume 1,375
Short Ratio
Av. Daily Volume 5,767

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 commencement of enrollment announced January 31, 2018. Top-line data due 1H 2019.
IMM-529
C. difficile infection
Phase 2 data due late-2Q 2019.
IMM-124E
Alcoholic steatohepatitis (ASH)
Phase 2 Interim analysis July 10, 2017 showed no statistical difference with placebo. However, company noted March 8, 2018 that top-line data were positive.
IMM-124E
Nonalcoholic steatohepatitis (NASH)
Phase 2 data due late-2019
IMM-124E
Nonalcoholic fatty liver disease (NAFLD) - pediatric